Literature DB >> 24001240

Viewpoint: scaling up testing services for non-communicable diseases in Africa: priorities for implementation research.

S Jaffar1, A Amberbir, N Kayuni, C Musicha, M Nyirenda.   

Abstract

The burden of non-communicable diseases in Africa is rising rapidly and implementation of evidence-based control strategies is needed urgently. Testing people for hypertension and diabetes will be an important component in the fight against these diseases, as voluntary counselling and testing was for HIV-infection. We discuss the below the areas where we believe evidence is needed to inform policy.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Africa; HIV-infection; cardiovascular disease; implementation research; non-communicable diseases; research priorities; screening

Mesh：

Year:  2013        PMID： 24001240     DOI： 10.1111/tmi.12180

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN： 1360-2276            Impact factor:   2.622


  3 in total

1.  Towards reframing health service delivery in Uganda: the Uganda Initiative for Integrated Management of Non-Communicable Diseases.

Authors:  Jeremy I Schwartz; Ashley Dunkle; Ann R Akiteng; Doreen Birabwa-Male; Richard Kagimu; Charles K Mondo; Gerald Mutungi; Tracy L Rabin; Michael Skonieczny; Jamila Sykes; Harriet Mayanja-Kizza
Journal:  Glob Health Action       Date:  2015-01-05       Impact factor: 2.640

2.  Novel approaches to screening for noncommunicable diseases: Lessons from Neno, Malawi.

Authors:  Chiyembekezo Kachimanga; Katie Cundale; Emily Wroe; Lawrence Nazimera; Arnold Jumbe; Elizabeth Dunbar; Noel Kalanga
Journal:  Malawi Med J       Date:  2017-06       Impact factor: 0.875

3.  Lung function and atherosclerosis: a cross-sectional study of multimorbidity in rural Uganda.

Authors:  Rebecca F Gilbert; Cody Cichowitz; Prossy Bibangambah; June-Ho Kim; Linda C Hemphill; Isabelle T Yang; Ruth N Sentongo; Bernard Kakuhikire; David C Christiani; Alexander C Tsai; Samson Okello; Mark J Siedner; Crystal M North
Journal:  BMC Pulm Med       Date:  2022-01-05       Impact factor: 3.317
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.